TrialPloS one2022
Predictive factors requiring high-dose evocalcet in hemodialysis patients with secondary hyperparathyroidism.
Masanori Tokumoto et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
2 papers cite it
this papercites it